Apart from PD-L1, metformin has also been found to interact with other immune regulators, including inhibitory immune checkpoints, M2-like tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells (MDSCs), thereby inhibiting immune destruction. This evidence concerns the gene CD274 and neoplasm.